TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10509040

Group type: EXPERIMENTAL
Intervention: ABVD plus STNI (supradiaphragmatic radiotherapy and para-aortic irradiation)
Number of subjects: 73

Group type: COMPARATOR
Intervention: STNI (supradiaphragmatic radiotherapy and para-aortic irradiation)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: ABVD plus STNI
Number of subjects: 73

Group type: COMPARATOR
Intervention: STNI
Number of subjects: 73
Study: 8903493

Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0
Study: 1863827

Group type: EXPERIMENTAL
Intervention: Nasal calcitonin (400 iu)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6666645

Group type: EXPERIMENTAL
Intervention: nomifensine 25-50 mg taken three times daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Motipress (1.5 mg fluphenazine with 30 mg nortriptyline) taken once daily
Number of subjects: 57
Study: 29952695

Group type: EXPERIMENTAL
Intervention: ACTIVE training
Number of subjects: 40
Study: 29625095

Group type: EXPERIMENTAL
Intervention: STarT Back risk group (low, medium, high)
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Medium-risk group
Number of subjects: 1109

Group type: COMPARATOR
Intervention: High-risk group
Number of subjects: 1109
Study: 27932449

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate 200 mg twice daily
Number of subjects: 88
Study: 26594629

Group type: EXPERIMENTAL
Intervention: fMRI analysis of autistic participants solving RSPM problems
Number of subjects: 0

Group type: COMPARATOR
Intervention: fMRI analysis of non-autistic participants solving RSPM problems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychophysiological interaction analyses (PPI) in autistic participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPI analyses in non-autistic participants
Number of subjects: 0
Study: 23440726

Group type: EXPERIMENTAL
Intervention: Blindfolded pursuers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sighted pursuers
Number of subjects: 0
Study: 21719364

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin Glargine (IG)
Number of subjects: 0
Study: 19090898

Group type: EXPERIMENTAL
Intervention: Heparin lock six times a week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heparin lock three times a week
Number of subjects: 30
Study: 16542788

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) with radiation therapy (RT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Sequential chemotherapy (CT) followed by radiation therapy (RT)
Number of subjects: 214
Study: 12669013

Group type: EXPERIMENTAL
Intervention: DASH dietary pattern
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study: 10727072

Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO2max) in premenarcheal girls
Number of subjects: 41

Group type: COMPARATOR
Intervention: Maximal oxygen uptake (VO2max) in young adult women
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Allometric scaling of VO2max
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Average maximal cardiac output
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Maximal stroke volume
Number of subjects: 41
Study: 9101194

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with intraoperative application of 0.1 mg/ml mitomycin C
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard trabeculectomy (Control)
Number of subjects: 48
Study: 7963199

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTCA)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Combined CABG and PTCA
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: CABG or PTCA
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: CABG or PTCA in younger cohort
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: CABG or PTCA in older cohort
Number of subjects: 432
Study: 3790403

Group type: EXPERIMENTAL
Intervention: 20 mg biphasic release tablet of nifedipine
Number of subjects: 0
Study: 27832062

Group type: EXPERIMENTAL
Intervention: Combined exercise protocol (free weight exercises intercalating aerobic exercise)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Free weight exercises
Number of subjects: 3

Group type: COMPARATOR
Intervention: Machine exercises
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combined exercise protocol
Number of subjects: 3

Group type: COMPARATOR
Intervention: Machine and free weight protocols
Number of subjects: 3
Study: 26501506

Group type: EXPERIMENTAL
Intervention: Education intervention about the usefulness of AD biomarkers (n = 119)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo group reading general information about the ADRC (n = 100)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: General public sample (n = 1418)
Number of subjects: 219
Study: 22437967

Group type: EXPERIMENTAL
Intervention: Low level fluence 810 nm (15 Joules/cm(2)) laser diode therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nontreated shaved control areas
Number of subjects: 17
Study: 20356626

Group type: EXPERIMENTAL
Intervention: Incredible Years program (16 weeks, group format)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Waiting list (Control group)
Number of subjects: 35
Study: 18373036

Group type: EXPERIMENTAL
Intervention: PLASA intervention group
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1120
Study: 15853819

Group type: EXPERIMENTAL
Intervention: Combination therapy with PTU (100 mg twice a day), propranolol (40 mg twice a day), and cholestyramine (4 g twice a day) for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: PTU (100 mg twice a day) and propranolol (40 mg twice a day) for 4 weeks
Number of subjects: 30
Study: 12456913

Group type: EXPERIMENTAL
Intervention: Preterm children
Number of subjects: 26

Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 26
Study: 10713872

Group type: COMPARATOR
Intervention: N2O (20, 40, 60, and 70% inhaled at 20-min intervals)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ketamine (0.4 mg kg‐1 + 1.0 mg kg‐1h‐1)
Number of subjects: 14
Study: 7547843

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both test meals
Number of subjects: 31
Study: 2011259

Group type: EXPERIMENTAL
Intervention: Pramiracetam (up to 4,000 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 548219

Group type: EXPERIMENTAL
Intervention: Right visual hemifield presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left visual hemifield presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Block presentation of visual fields
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Signal detection procedures
Number of subjects: 0
Study: 31251351

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) treatment at a dosage of 20 mg/kg before cardiac catheterization.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 0
Study: 27886686

Group type: EXPERIMENTAL
Intervention: Preoperative warfarin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative warfarin therapy
Number of subjects: 0
Study: 25488505

Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Treatment Control Condition (TCC)
Number of subjects: 52
Study: 24063360

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 150
Study: 17076695

Group type: EXPERIMENTAL
Intervention: S-3304 800 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: S-3304 1600 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: S-3304 2400 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: S-3304 3200 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: S-3304 (all doses)
Number of subjects: 32
Study: 15023580

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Siblings of schizophrenia patients
Number of subjects: 153

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 153
Study: 11003605

Group type: EXPERIMENTAL
Intervention: 15(S)-HETE
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LTB(4) production
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Macrophages and neutrophils
Number of subjects: 25
Study: 9487416

Group type: EXPERIMENTAL
Intervention: Treatment A (glucose 25g i.v. with insulin 10 units i.v.)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Treatment B (50 mmol of 8.4% sodium bicarbonate infusion)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Treatment C (0.5mg of salbutamol i.v. in 50mls 5% dextrose)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Treatment D (combination of treatments A and B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Treatment E (combination of treatment B and C)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Treatment F (combination of treatments A and C)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Treatment G (combination of treatments A, B, and C)
Number of subjects: 70
Study: 8368735

Group type: EXPERIMENTAL
Intervention: VMCL alone
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: VMCL plus low dose cyclophosphamide
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: VMCL treatment
Number of subjects: 384

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 384
Study: 3530861

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) tablets
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ranitidine (R)
Number of subjects: 75
Study: 30715010

Group type: EXPERIMENTAL
Intervention: Group A (tourniquet and suction drainage)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Group B (no tourniquet or suction drainage)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Group C (tourniquet only)
Number of subjects: 151
Study: 30382190

Group type: COMPARATOR
Intervention: Type 2 diabetes
Number of subjects: 6823

Group type: COMPARATOR
Intervention: HbA1c<53 mmol/mol
Number of subjects: 6823

Group type: EXPERIMENTAL
Intervention: Higher illness duration in diabetes subsample
Number of subjects: 6823

Group type: EXPERIMENTAL
Intervention: Presence of type 2 diabetes, depressive symptoms, and BMI
Number of subjects: 6823

Group type: EXPERIMENTAL
Intervention: Apnoea
Number of subjects: 6823
Study: 26574551

Group type: EXPERIMENTAL
Intervention: Exposure to e-cigarette advertisements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ad exposure)
Number of subjects: 0
Study: 25171459

Group type: EXPERIMENTAL
Intervention: Shikani optical stylet (SOS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 120
Study: 21551317

Group type: EXPERIMENTAL
Intervention: Extended-release (ER) propiverine 45 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immediate-release (IR) propiverine 30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fat-rich meal before administration of propiverine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fat-rich meal effect on ER propiverine
Number of subjects: 24
Study: 19280455

Group type: EXPERIMENTAL
Intervention: RightWay Café game
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16625377

Group type: EXPERIMENTAL
Intervention: Ileocaecal interposition (ICI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Colon-J-pouch (CJP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CJP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ICI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ICI and CJP
Number of subjects: 30
Study: 15117517

Group type: EXPERIMENTAL
Intervention: In-home test weights for measuring milk intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: No in-home test weights (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 0
Study: 12486585

Group type: EXPERIMENTAL
Intervention: S‐(+)‐ketamine/propofol (K/P)
Number of subjects: 145

Group type: COMPARATOR
Intervention: alfentanil/propofol (A/P)
Number of subjects: 145
Study: 9485094

Group type: EXPERIMENTAL
Intervention: zoledronate (200 or 400 microg)
Number of subjects: 28
Study: 7630148

Group type: EXPERIMENTAL
Intervention: CNS 1102 (2 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2774588

Group type: EXPERIMENTAL
Intervention: Cepharanthine (50 mg intravenously every day during postoperative chemotherapy)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no administration of Cepharanthine)
Number of subjects: 34
Study: 303115

Group type: EXPERIMENTAL
Intervention: Benoxaprofen 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benoxaprofen 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benoxaprofen 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benoxaprofen 25 mg every 24 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benoxaprofen 50 mg every 24 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benoxaprofen 100 mg every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benoxaprofen with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milled benoxaprofen (19 micron)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benoxaprofen (various doses)
Number of subjects: 0
Study: 31812127

Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 126

Group type: COMPARATOR
Intervention: Carbamazepine controlled-release (carbamazepine-CR)
Number of subjects: 126
Study: 31667519

Group type: EXPERIMENTAL
Intervention: BCAA-reduced diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (isocaloric diet with BCAAs)
Number of subjects: 0
Study: 28031191

Group type: EXPERIMENTAL
Intervention: Controlled diet approximating habitual food intake for 2 weeks
Number of subjects: 153
Study: 26193059

Group type: EXPERIMENTAL
Intervention: Exercise: 5 days/week, 400 or 600 kcal/session, 10 months
Number of subjects: 74
Study: 24979880

Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate 80 mg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 160
Study: 21195260

Group type: EXPERIMENTAL
Intervention: Quad-helix or expansion plate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (normal occlusion)
Number of subjects: 35
Study: 19690194

Group type: EXPERIMENTAL
Intervention: Formalin‐fixed, paraffin‐embedded (FFPE) tissue samples
Number of subjects: 3278

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry tests for p53 and SMAD4
Number of subjects: 3278

Group type: EXPERIMENTAL
Intervention: TERT immunohistochemistry test
Number of subjects: 3278

Group type: EXPERIMENTAL
Intervention: Messenger RNA retrieval for expression profiling
Number of subjects: 3278
Study: 17309451

Group type: EXPERIMENTAL
Intervention: CDP + BPO (clindamycin phosphate 1% + benzoyl peroxide 5%)
Number of subjects: 148

Group type: COMPARATOR
Intervention: ERY + Zn (erythromycin 4% + zinc acetate 1.2%)
Number of subjects: 148
Study: 15225185

Group type: EXPERIMENTAL
Intervention: PROM test (rapid dipstick method for IGFBP-1 detection)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Nitrazine test
Number of subjects: 151

Group type: COMPARATOR
Intervention: Amniotic Fluid Index (AFI) measured by four-quadrant method
Number of subjects: 151
Study: 11322638

Group type: EXPERIMENTAL
Intervention: Orengedoku‐to (Huanglian‐Jie‐Du‐Tang) granules (7.5 g daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Kakkon‐to (Ge‐Gen‐Tang) granules (7.5 g daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sairei‐to (Cai‐Ling‐Tang) granules (9.0 g daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no herbal medicine)
Number of subjects: 54
Study: 9823342

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Timolol + Dorzolamide
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 7524798

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (3 g/375 mg every six hours)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Clindamycin (600 mg every six hours) plus gentamicin (2.5 mg to 5.0 mg/kg every eight to 12 hours)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 331

Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin
Number of subjects: 331
Study: 3286535

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 32
Study: 28969467

Group type: EXPERIMENTAL
Intervention: PPD screening during months 1 to 12 postpartum
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: PPD screening through 12 months postpartum
Number of subjects: 152
Study: 26860809

Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (10g daily for 2 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24627419

Group type: EXPERIMENTAL
Intervention: Mipomersen 30 mg once daily
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mipomersen 70 mg 3 times weekly
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg once weekly
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 23747584

Group type: EXPERIMENTAL
Intervention: self-help continuing care
Number of subjects: 90

Group type: COMPARATOR
Intervention: assessment-only
Number of subjects: 90
Study: 19918189

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab delivered using the ClearWay RX catheter
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 150
Study: 18596303

Group type: EXPERIMENTAL
Intervention: Telephone intervention for 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study: 15746682

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 40 mg in addition to gemeprost 1 mg up to 3 times daily for 2 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gemeprost alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 40 mg in addition to gemeprost
Number of subjects: 80
Study: 14728309

Group type: EXPERIMENTAL
Intervention: SysBank knowledge base
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SysBank
Number of subjects: 0
Study: 11045887

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 12
Study: 8923992

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 1744

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 1744
Study: 1307234

Group type: EXPERIMENTAL
Intervention: Vitamin supplement (containing 12 vitamins including 0.8 mg of folic acid)
Number of subjects: 4753

Group type: COMPARATOR
Intervention: Trace-element supplement (containing copper, manganese, zinc, and a very low dose of vitamin C)
Number of subjects: 4753
Study: 6364774

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU, d‐alpha‐tocopheryl acetate, by mouth twice daily for 20 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (by mouth twice daily for 20 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31524943

Group type: EXPERIMENTAL
Intervention: Saline + rifampicin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Saline + 10% povidone iodine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 300
Study: 28438655

Group type: EXPERIMENTAL
Intervention: Foundational articles
Number of subjects: 101

Group type: COMPARATOR
Intervention: Functional classics
Number of subjects: 101

Group type: COMPARATOR
Intervention: Endovascular classics
Number of subjects: 101

Group type: COMPARATOR
Intervention: Spine classics
Number of subjects: 101
Study: 25519041

Group type: EXPERIMENTAL
Intervention: Taxanes plus bevacizumab plus capecitabine (TBX)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Taxanes plus bevacizumab (TB)
Number of subjects: 432
Study: 23263773

Group type: EXPERIMENTAL
Intervention: LY2599506
Number of subjects: 0
Study: 21303197

Group type: EXPERIMENTAL
Intervention: Neurofeedback using the Peak Brain Happiness Trainer(™) system
Number of subjects: 12
Study: 19827527

Group type: EXPERIMENTAL
Intervention: Combined therapy with quinapril (23.3 ± 9.8 mg) and indapamide (1.5 mg)
Number of subjects: 60
Study: 16670131

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAP-BAND System)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Very-low-calorie diets, pharmacotherapy, and lifestyle change
Number of subjects: 80
Study: 12916451

Group type: EXPERIMENTAL
Intervention: Open questions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed questions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reciprocity indices
Number of subjects: 0
Study: 10325261

Group type: EXPERIMENTAL
Intervention: Trimegestone (0.05, 0.1, 0.25 and 0.5 mg per day) with continuous micronized oestradiol 2 mg daily for six treatment cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimegestone-treated endometrium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimegestone (various doses)
Number of subjects: 0
Study: 8609099

Group type: EXPERIMENTAL
Intervention: Oral slow-release albuterol 8 mg, twice-daily (b.i.d.)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral slow-release albuterol 8 mg, once daily at night
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 1960379

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 90
Study: 7202827

Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tizolemide 100 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16